HER2-Positive Breast Cancer

Focused on HER2-targeted therapies such as trastuzumab, pertuzumab, and novel agents like tucatinib, this track dives into treatment evolution and resistance challenges. Attendees will explore dual HER2 blockade, ADCs, and the role of HER2-low classification in guiding future treatment landscapes.

 

    Related Conference of HER2-Positive Breast Cancer

    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    HER2-Positive Breast Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in